A detailed history of Charles Schwab Investment Management Inc transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 221,997 shares of TARS stock, worth $6.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
221,997
Previous 218,662 1.53%
Holding current value
$6.03 Million
Previous $4.43 Million 82.27%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$19.61 - $39.22 $65,399 - $130,798
3,335 Added 1.53%
221,997 $8.07 Million
Q4 2023

Feb 06, 2024

BUY
$12.98 - $20.73 $392,878 - $627,455
30,268 Added 16.07%
218,662 $4.43 Million
Q3 2023

Nov 08, 2023

BUY
$14.75 - $24.62 $527,017 - $879,672
35,730 Added 23.4%
188,394 $3.35 Million
Q2 2023

Aug 09, 2023

BUY
$11.57 - $19.63 $156,345 - $265,260
13,513 Added 9.71%
152,664 $2.76 Million
Q1 2023

May 11, 2023

BUY
$11.92 - $16.27 $7,152 - $9,762
600 Added 0.43%
139,151 $1.75 Million
Q4 2022

Feb 13, 2023

BUY
$14.12 - $18.72 $30,654 - $40,641
2,171 Added 1.59%
138,551 $2.03 Million
Q3 2022

Nov 14, 2022

BUY
$14.08 - $18.5 $614,549 - $807,469
43,647 Added 47.07%
136,380 $2.34 Million
Q2 2022

Aug 15, 2022

BUY
$11.08 - $19.08 $489,182 - $842,381
44,150 Added 90.88%
92,733 $1.35 Million
Q1 2022

May 13, 2022

BUY
$14.49 - $24.28 $20,314 - $34,040
1,402 Added 2.97%
48,583 $818,000
Q4 2021

Feb 11, 2022

BUY
$21.21 - $29.68 $8,802 - $12,317
415 Added 0.89%
47,181 $1.06 Million
Q3 2021

Nov 16, 2021

BUY
$21.45 - $29.22 $4,139 - $5,639
193 Added 0.41%
46,766 $1.01 Million
Q2 2021

Aug 16, 2021

BUY
$27.16 - $38.59 $134,442 - $191,020
4,950 Added 11.89%
46,573 $1.35 Million
Q1 2021

May 17, 2021

BUY
$27.37 - $47.25 $120,428 - $207,900
4,400 Added 11.82%
41,623 $1.34 Million
Q4 2020

Feb 16, 2021

BUY
$19.17 - $49.62 $713,564 - $1.85 Million
37,223 New
37,223 $1.54 Million

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $725M
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.